A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body

NCT07221591 · Active, not recruiting

Last updated 2026-05-28

This study compares how two different versions of the drug survodutide are absorbed by the body in healthy participants.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 100 people

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2025-11 · est. completion 2026-08

Where 2 sites · Germany

What this study is testing ClinicalTrials.gov NCT07221591 ↗

Description as written by the study sponsor.

This study is open to healthy people between 18 and 65 years of age. People can join the study if they have a body mass index between 27 and 39.9 kg/m2. The purpose of this study is to test a new formulation of a medicine called survodutide. Survodutide is being developed to help people with obesity and people with liver conditions. When a new formulation is developed, it is important to understand how it is taken up by the body. Participants are divided into 2 groups by chance. One group gets the reference formulation of survodutide (formulation A). The other group gets the new formulation of survodutide (formulation B2). Participants in both groups inject survodutide under their skin once a week for about 6 and a half months. Participants are in the study for about 7 months. During this time, they visit the study site 15 times. For one of the visits, participants stay overnight for 3 nights at the study site. The site staff takes blood samples to measure how much survodutide is in the blood. They also check participants' health and take note of any unwanted effects.

Treatments tested

survodutide Combination Product

survodutide, pre-filled syringe

Main thing measured	Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)
Sponsor	Boehringer Ingelheim
Conditions studied	Healthy
GLP-1 drugs	survodutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07221591 ↗